Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
1 other identifier
interventional
5,993
35 countries
477
Brief Summary
The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
477 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2002
CompletedFirst Submitted
Initial submission to the registry
September 2, 2005
CompletedFirst Posted
Study publicly available on registry
September 5, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedResults Posted
Study results publicly available
August 17, 2009
CompletedMay 20, 2014
April 1, 2014
5.2 years
September 2, 2005
February 21, 2009
May 15, 2014
Conditions
Outcome Measures
Primary Outcomes (2)
Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
From day 30 to 4 years
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.
From day 30 to 4 years
Secondary Outcomes (85)
Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.
Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days
Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
From day 30 to 4 years
Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years
From day 30 to 4 years
Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years
From day 30 to 4 years
- +80 more secondary outcomes
Other Outcomes (13)
Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)
Day 1 to completion of double blinded treatment plus 30 days
Incidence Rate of Serious Adverse Event (Preferred Term = Angina)
Day 1 to completion of double blinded treatment plus 30 days
Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)
Day 1 to completion of double blinded treatment plus 30 days
- +10 more other outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Written informed consent.
- Male or female patients 40 years of age or older.
- Smoking history of at least 10 pack years.
- Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted normal and FEV1\<70% of FVC and on stable respiratory medication.
You may not qualify if:
- Significant diseases other than COPD which in the opinion of the investigator may put the patient at risk or influence the patients ability to participate.
- Myocardial infarction in past 6 months.
- Unstable or life threatening arrhythmia in past year.
- Hospitalization for NYHA heart failure class III or IV in past year.
- Active tuberculosis.
- Asthma.
- Pulmonary resection.
- Malignancy treated with radiation or chemotherapy in past 5 years.
- Respiratory infection in 4 weeks prior to screening.
- Known hypersensitivity to anticholinergic drugs or components.
- Known moderate to severe renal impairment.
- Known narrow angle glaucoma.
- Significant symptomatic BPH or bladder neck obstruction.
- Need for oxygen therapy \>12 hr/day.
- Use of oral corticosteroids at unstable doses or \>10 mg/day.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (490)
205.235.3779 Boehringer Ingelheim Investigational Site
Anniston, Alabama, United States
205.235.3785 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
205.235.3804 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States
205.235.3795 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
205.235.3759 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
205.235.3770 Boehringer Ingelheim Investigational Site
Carmichael, California, United States
205.235.3778 Boehringer Ingelheim Investigational Site
Escondito, California, United States
205.235.3810 Boehringer Ingelheim Investigational Site
Lakewood, California, United States
205.235.3758 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
205.235.3812 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
205.235.3773 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
205.235.3800 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
205.235.3802 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
205.235.3786 Pulmonary and Critical Care Medicine
Orange, California, United States
205.235.3811 Boehringer Ingelheim Investigational Site
Palo Alto, California, United States
205.235.3741 Boehringer Ingelheim Investigational Site
Rancho Mirage, California, United States
205.235.3717 Boehringer Ingelheim Investigational Site
San Diego, California, United States
205.235.3781 Boehringer Ingelheim Investigational Site
San Diego, California, United States
205.235.3784 Boehringer Ingelheim Investigational Site
San Diego, California, United States
205.235.3760 Boehringer Ingelheim Investigational Site
Sepulveda, California, United States
205.235.3711 Boehringer Ingelheim Investigational Site
Stockton, California, United States
205.235.3764 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
205.235.3783 Boehringer Ingelheim Investigational Site
Wheat Ridge, Colorado, United States
205.235.3727 Boehringer Ingelheim Investigational Site
Hartford, Connecticut, United States
205.235.3808 Boehringer Ingelheim Investigational Site
Hartford, Connecticut, United States
205.235.3793 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut, United States
205.235.3815 Boehringer Ingelheim Investigational Site
West Haven, Connecticut, United States
205.235.3706 Boehringer Ingelheim Investigational Site
Bay Pines, Florida, United States
205.235.3762 Boehringer Ingelheim Investigational Site
Brandon, Florida, United States
205.235.3707 Boehringer Ingelheim Investigational Site
Largo, Florida, United States
205.235.3703 Boehringer Ingelheim Investigational Site
Melbourne, Florida, United States
205.235.3775 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
205.235.3743 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
205.235.3756 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
205.235.3739 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida, United States
205.235.3719 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
205.235.3790 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
205.235.3716 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
205.235.3794 Boehringer Ingelheim Investigational Site
Stockbridge, Georgia, United States
205.235.3724 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho, United States
205.235.3713 Boehringer Ingelheim Investigational Site
Normal, Illinois, United States
205.235.3768 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
205.235.3749 Boehringer Ingelheim Investigational Site
Dubuque, Iowa, United States
205.235.3757 Boehringer Ingelheim Investigational Site
Olathe, Kansas, United States
205.235.3729 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
205.235.3737 Boehringer Ingelheim Investigational Site
Metairie, Louisiana, United States
205.235.3788 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
205.235.3750 Boehringer Ingelheim Investigational Site
Bidderford, Maine, United States
205.235.3806 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
205.235.3721 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
205.235.3726 354 Birnie Ave
Springfield, Massachusetts, United States
205.235.3813 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan, United States
205.235.3732 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
205.235.3809 Boehringer Ingelheim Investigational Site
Livonia, Michigan, United States
205.235.3751 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
205.235.3754 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
205.235.3789 Boehringer Ingelheim Investigational Site
Rochester, Minnesota, United States
205.235.3734 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri, United States
205.235.3814 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
205.235.3747 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
205.235.3763 Boehringer Ingelheim Investigational Site
Lebanon, New Hampshire, United States
205.235.3797 Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
205.235.3799 Boehringer Ingelheim Investigational Site
Summit, New Jersey, United States
205.235.3796 Boehringer Ingelheim Investigational Site
Albany, New York, United States
205.235.3807 Boehringer Ingelheim Investigational Site
Bay Shore, New York, United States
205.235.3765 Boehringer Ingelheim Investigational Site
Larchmont, New York, United States
205.235.3748 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
205.235.3818 Boehringer Ingelheim Investigational Site
New York, New York, United States
205.235.3722 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
205.235.3816 Boehringer Ingelheim Investigational Site
The Bronx, New York, United States
205.235.3730 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
205.235.3731 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina, United States
205.235.3736 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
205.235.3745 Boehringer Ingelheim Investigational Site
Elizabath City, North Carolina, United States
205.235.3712 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
205.235.3723 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
205.235.3701 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
205.235.3791 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
205.235.3820 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
205.235.3725 Boehringer Ingelheim Investigational Site
Hershey, Pennsylvania, United States
205.235.3817 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
205.235.3715 Boehringer Ingelheim Investigational Site
Providence, Rhode Island, United States
205.235.3803 Boehringer Ingelheim Investigational Site
El Paso, Texas, United States
205.235.3742 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
205.235.3787 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
205.235.3704 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
205.235.3752 Boehringer Ingelheim Investigational Site
Salt Lake City, Utah, United States
205.235.3744 Boehringer Ingelheim Investigational Site
Danville, Virginia, United States
205.235.3782 Boehringer Ingelheim Investigational Site
Fredericksburg, Virginia, United States
205.235.3771 Boehringer Ingelheim Investigational Site
Lynchburg, Virginia, United States
205.235.3738 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
205.235.3792 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
205.235.3761 Boehringer Ingelheim Investigational Site
Salem, Virginia, United States
205.235.3718 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
205.235.3780 Boehringer Ingelheim Investigational Site
La Crosse, Wisconsin, United States
205.235.101
Buenos Aires, Argentina
205.235.101 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
205.235.103 Hospital Alemán
Capital Federal, Argentina
205.235.104 Hospital de Clinicas José de San Martín
Capital Federal, Argentina
205.235.105 Hospital General de Agudos José María Ramos Mejía
Capital Federal, Argentina
205.235.107 Policlínica Bancaria
Capital Federal, Argentina
205.235.108 Hospital General de Agudos Dr. Enrique Tornú
Capital Federal, Argentina
205.235.109 Hospital Muñiz
Capital Federal, Argentina
205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.
Parque Velez Sarlfield, Argentina
205.235.102 Instituto Cardiovascular de Rosario
Rosario, Argentina
205.235.106 Hospital Cetrángolo
Vicente López, Argentina
205.235.0205 Boehringer Ingelheim Investigational Site
Bankstown, New South Wales, Australia
205.235.0202 Boehringer Ingelheim Investigational Site
Concord, New South Wales, Australia
205.235.0209 Boehringer Ingelheim Investigational Site
Westmead, New South Wales, Australia
205.235.0204 Boehringer Ingelheim Investigational Site
Cairns, Queensland, Australia
205.235.0203 Boehringer Ingelheim Investigational Site
Redcliffe, Queensland, Australia
205.235.0207 Boehringer Ingelheim Investigational Site
Port Lincoln, South Australia, Australia
205.235.0206 Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
205.235.0201 Boehringer Ingelheim Investigational Site
Geelong, Victoria, Australia
205.235.0303 Boehringer Ingelheim Investigational Site
Graz, Austria
205.235.0305 Boehringer Ingelheim Investigational Site
Innsbruck, Austria
205.235.0304 Boehringer Ingelheim Investigational Site
Leoben, Austria
205.235.0301 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.235.0302 Boehringer Ingelheim Investigational Site
Vienna, Austria
205.235.0439 Boehringer Ingelheim Investigational Site
Anderlecht, Belgium
205.235.0429 Boehringer Ingelheim Investigational Site
Baudour, Belgium
205.235.0421 Boehringer Ingelheim Investigational Site
Bruges, Belgium
205.235.0424 Boehringer Ingelheim Investigational Site
Brussels, Belgium
205.235.0432 Boehringer Ingelheim Investigational Site
Brussels, Belgium
205.235.0434 Boehringer Ingelheim Investigational Site
Brussels, Belgium
205.235.0422 Boehringer Ingelheim Investigational Site
Dendermonde, Belgium
205.235.0405 Boehringer Ingelheim Investigational Site
Edegem, Belgium
205.235.0414 Boehringer Ingelheim Investigational Site
Ghent, Belgium
205.235.0418 U.Z. Gent
Ghent, Belgium
205.235.0417 Boehringer Ingelheim Investigational Site
Herentals, Belgium
205.235.0402 Boehringer Ingelheim Investigational Site
Ieper, Belgium
205.235.0409 Boehringer Ingelheim Investigational Site
Kortrijk, Belgium
205.235.0407 Boehringer Ingelheim Investigational Site
Leuven, Belgium
205.235.0440 Boehringer Ingelheim Investigational Site
Luxembourg, Belgium
205.235.0403 Boehringer Ingelheim Investigational Site
Menen, Belgium
205.235.0406 Boehringer Ingelheim Investigational Site
Merksem, Belgium
205.235.0404 Boehringer Ingelheim Investigational Site
Middelheim, Belgium
205.235.0438 Boehringer Ingelheim Investigational Site
Mons, Belgium
205.235.0437 Boehringer Ingelheim Investigational Site
Namur, Belgium
205.235.0420 Boehringer Ingelheim Investigational Site
Neerpelt, Belgium
205.235.0435 Boehringer Ingelheim Investigational Site
Nobressart (attert), Belgium
205.235.0423 Boehringer Ingelheim Investigational Site
Ostend, Belgium
205.235.0433 Boehringer Ingelheim Investigational Site
Tournai, Belgium
205.235.0412 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
205.235.0413 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
205.235.0428 Boehringer Ingelheim Investigational Site
Yvoir, Belgium
205.235.510 Servico de Pneumologia
Florianópolis - SC, Brazil
205.235.508
Juiz de Fora - MG, Brazil
205.235.501
Porto Alegre - RS, Brazil
205.235.503
Porto Alegre - RS, Brazil
205.235.506
Porto Alegre - RS, Brazil
205.235.507 Depto.de Medicina Interna-Servico de pneumologia
Porto Alegre - RS, Brazil
205.235.502
Rio de Janeiro - RJ, Brazil
205.235.505 Dep.Medicina Especializada (DEMESP)
Rio de Janeiro - RJ, Brazil
205.235.511 Departamento de Pneumologia
Salvador - BA, Brazil
205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar
Santo André - SP, Brazil
205.235.512
São Paulo - SP, Brazil
205.235.513
São Paulo - SP, Brazil
205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina
São Paulo - SP, Brazil
205.235.515 Lar Escola São Francisco / Setor de Pneumologia
São Paulo - SP, Brazil
205.235.0712 Boehringer Ingelheim Investigational Site
Benešov, Czechia
205.235.0711 Boehringer Ingelheim Investigational Site
Beroun, Czechia
205.235.0718 Clinic of Functional Diagnostics and Rehabilitation
Brno, Czechia
205.235.0725 University Hospital Brno
Brno, Czechia
205.235.0720 Office of Pulmonology and Respiratory Diseases
Český Těšín, Czechia
205.235.0717 Pulmonary Clinic
Hradec Králové, Czechia
205.235.0705 Boehringer Ingelheim Investigational Site
Jablonec nad Nisou, Czechia
205.235.0726 Private Office of Pulmonary Diseases
Jaroměř, Czechia
205.235.0722 Hospital Kromeriz
Kroměříž, Czechia
205.235.0724 District Hospital Kyjov
Kyjov, Czechia
205.235.0704 Boehringer Ingelheim Investigational Site
Lovosice, Czechia
205.235.0702 Boehringer Ingelheim Investigational Site
Mariánské Lázně, Czechia
205.235.0701 Boehringer Ingelheim Investigational Site
Pilsen, Czechia
205.235.0703 Boehringer Ingelheim Investigational Site
Pilsen, Czechia
205.235.0706 Boehringer Ingelheim Investigational Site
Prague, Czechia
205.235.0707 Boehringer Ingelheim Investigational Site
Prague, Czechia
205.235.0709 Boehringer Ingelheim Investigational Site
Prague, Czechia
205.235.0710 Boehringer Ingelheim Investigational Site
Prague, Czechia
205.235.0715 Boehringer Ingelheim Investigational Site
Prague, Czechia
205.235.0708 Boehringer Ingelheim Investigational Site
Praha 5 - Nove Butovice, Czechia
205.235.0723 Office of Pulmonary and Respiratory Diseases
Přerov, Czechia
205.235.0721 Office of Pulmonary Diseases
Příbor, Czechia
205.235.0713 Boehringer Ingelheim Investigational Site
Strakonice, Czechia
205.235.0714 Boehringer Ingelheim Investigational Site
Tábor, Czechia
205.235.0719 Office of Pulmonology and Respiratory Diseases
Ústí nad Orlicí, Czechia
205.235.0716 Boehringer Ingelheim Investigational Site
Znojmo, Czechia
205.235.0804 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
205.235.0826 Boehringer Ingelheim Investigational Site
Aalborg SV, Denmark
205.235.0803 Boehringer Ingelheim Investigational Site
Aarhus, Denmark
205.235.0831 Boehringer Ingelheim Investigational Site
Copenhagen, Denmark
205.235.0828 Boehringer Ingelheim Investigational Site
Copenhagen K, Denmark
205.235.0802 Boehringer Ingelheim Investigational Site
Copenhagen NV, Denmark
205.235.0816 Boehringer Ingelheim Investigational Site
Elsinore, Denmark
205.235.0807 Boehringer Ingelheim Investigational Site
Fåborg, Denmark
205.235.0821 Boehringer Ingelheim Investigational Site
Frederikshavn, Denmark
205.235.0832 Boehringer Ingelheim Investigational Site
Frederikssund, Denmark
205.235.0805 Boehringer Ingelheim Investigational Site
Hellerup, Denmark
205.235.0835 Boehringer Ingelheim Investigational Site
Hellerup, Denmark
205.235.0811 Boehringer Ingelheim Investigational Site
Hillerød, Denmark
205.235.0834 Boehringer Ingelheim Investigational Site
Hobro, Denmark
205.235.0806 Boehringer Ingelheim Investigational Site
Holbæk, Denmark
205.235.0814 Boehringer Ingelheim Investigational Site
Holstebro, Denmark
205.235.0801 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
205.235.0833 Boehringer Ingelheim Investigational Site
Kalundborg, Denmark
205.235.0830 Boehringer Ingelheim Investigational Site
Kolding, Denmark
205.235.0819 Boehringer Ingelheim Investigational Site
Nykøbing Falster, Denmark
205.235.0810 Boehringer Ingelheim Investigational Site
Næstved, Denmark
205.235.0809 Boehringer Ingelheim Investigational Site
Odense C, Denmark
205.235.0815 Boehringer Ingelheim Investigational Site
Randers, Denmark
205.235.0824 Boehringer Ingelheim Investigational Site
Silkeborg, Denmark
205.235.0813 Boehringer Ingelheim Investigational Site
Skive, Denmark
205.235.0822 Boehringer Ingelheim Investigational Site
Skive, Denmark
205.235.0820 Boehringer Ingelheim Investigational Site
Slagelse, Denmark
205.235.0808 Boehringer Ingelheim Investigational Site
Svendborg, Denmark
205.235.0827 Boehringer Ingelheim Investigational Site
Værløse, Denmark
205.235.0903 Boehringer Ingelheim Investigational Site
Helsinki, Finland
205.235.0901 Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
205.235.0905 Boehringer Ingelheim Investigational Site
Kotka, Finland
205.235.0904 Boehringer Ingelheim Investigational Site
Lahti, Finland
205.235.0902 Boehringer Ingelheim Investigational Site
Pori, Finland
205.235.1004 Clinique Toulouse Lautrec
Albi, France
205.235.1007 Cabinet Médical
Albi, France
205.235.1015 Centre Hospitalier
Barbezieux-Saint-Hilaire, France
205.235.1012 Cabinet Médical
Bourges, France
205.235.1024 Cabinet Médical
Chamalières, France
205.235.1006 Centre Hospitalier de Chauny
Chauny, France
205.235.1005 Polyclinique
Cholet, France
205.235.1013 Cabinet Médical
La Teste-de-Buch, France
205.235.1020 Cabinet Médical
Marseille, France
205.235.1023 Cabinet Médical
Montauban, France
205.235.1025 Centre Médical Erdre Saint Augustin
Nantes, France
205.235.1002 Cabinet médical
Nice, France
205.235.1001 Hôpital Bichat
Paris, France
205.235.1016 Cabinet Médical
Provins, France
205.235.1019 Cabinet Médical
Strasbourg, France
205.235.1009 Centre Hospitalier de Bigorre
Tarbes, France
205.235.1021 Clinique Pasteur
Toulouse, France
205.235.1113 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.235.1114 Boehringer Ingelheim Investigational Site
Berlin, Germany
205.235.1103 Boehringer Ingelheim Investigational Site
Brake, Germany
205.235.1105 Boehringer Ingelheim Investigational Site
Braunschweig, Germany
205.235.1104 Boehringer Ingelheim Investigational Site
Bruchsal, Germany
205.235.1115 Boehringer Ingelheim Investigational Site
Hanover, Germany
205.235.1109 Boehringer Ingelheim Investigational Site
Kaufbeuren, Germany
205.235.1108 Boehringer Ingelheim Investigational Site
Loerrach, Germany
205.235.1102 Boehringer Ingelheim Investigational Site
Lübeck, Germany
205.235.1106 Boehringer Ingelheim Investigational Site
München, Germany
205.235.1110 Boehringer Ingelheim Investigational Site
München, Germany
205.235.1101 Boehringer Ingelheim Investigational Site
Ulm, Germany
205.235.1107 Boehringer Ingelheim Investigational Site
Weyhe, Germany
205.235.1112 Boehringer Ingelheim Investigational Site
Wiesloch, Germany
205.235.1202 8th Pulmonology Clinic "Sotiria" Athens Chest Hospital
Athens, Greece
205.235.1203 Boehringer Ingelheim Investigational Site
Athens, Greece
205.235.1201 Boehringer Ingelheim Investigational Site
Heraklion, Greece
205.235.1211 Boehringer Ingelheim Investigational Site
Kavala, Greece
205.235.1204 Boehringer Ingelheim Investigational Site
Larissa, Greece
205.235.1209 Boehringer Ingelheim Investigational Site
Pátrai, Greece
205.235.1210 Boehringer Ingelheim Investigational Site
Pátrai, Greece
205.235.1205 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
205.235.1206 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
205.235.1207 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
205.235.1401 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
205.235.1403 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
205.235.1402 Boehringer Ingelheim Investigational Site
Kowloon, Hong Kong
205.235.1404 Boehringer Ingelheim Investigational Site
Kowloon, Hong Kong
205.235.1303 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.235.1308 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.235.1309 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.235.1310 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.235.1311 Boehringer Ingelheim Investigational Site
Budapest, Hungary
205.235.1318 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
205.235.1314 Boehringer Ingelheim Investigational Site
Deszk, Hungary
205.235.1306 Boehringer Ingelheim Investigational Site
Érd, Hungary
205.235.1315 Boehringer Ingelheim Investigational Site
Farkasgyepü, Hungary
205.235.1320 Boehringer Ingelheim Investigational Site
Gyula, Hungary
205.235.1307 Boehringer Ingelheim Investigational Site
Kiskunhalas, Hungary
205.235.1304 Boehringer Ingelheim Investigational Site
Miskolc, Hungary
205.235.1317 Boehringer Ingelheim Investigational Site
Mosonmagyaróvár, Hungary
205.235.1301 Boehringer Ingelheim Investigational Site
Pécs, Hungary
205.235.1313 Boehringer Ingelheim Investigational Site
Solymár, Hungary
205.235.1305 Boehringer Ingelheim Investigational Site
Sopron, Hungary
205.235.1319 Boehringer Ingelheim Investigational Site
Szombathely, Hungary
205.235.1302 Boehringer Ingelheim Investigational Site
Tatabánya, Hungary
205.235.1316 Boehringer Ingelheim Investigational Site
Törökbálint, Hungary
205.235.1312 Boehringer Ingelheim Investigational Site
Veszprém, Hungary
205.235.1501 Boehringer Ingelheim Investigational Site
Dublin, Ireland
205.235.1503 Boehringer Ingelheim Investigational Site
Dublin, Ireland
205.235.1505 Boehringer Ingelheim Investigational Site
Dublin, Ireland
205.235.1631 A. O. SS. Antonio e Biagio e Arrigo
Alessandria, Italy
205.235.1613 A. O. S. Giuseppe Moscati
Avellino, Italy
205.235.1618 Ospedale Bellaria
Bologna, Italy
205.235.1649 Ospedale di Circolo di Busto Arsizio
Busto Arsizio (VA), Italy
205.235.1635 P. O. Roberto Binaghi
Cagliari, Italy
205.235.1623 A. O. di Carrara
Carrara (Massa), Italy
205.235.1645 Ospedale Civile "Zappatoni"
Cassano D'adda (Milano), Italy
205.235.1617 Ospedale S. Camillo De Lellis
Chieti, Italy
205.235.1612 A. O. S. Antonio Abate
Erice (Trapani), Italy
205.235.1622 A. O. S. Anna
Ferrara, Italy
205.235.1646 A. O. di Careggi
Florence, Italy
205.235.1647 A. O. Careggi
Florence, Italy
205.235.1615 Ospedale S. Martino
Genova, Italy
205.235.1603 P. O. di Gubbio
Gubbio (Perugia), Italy
205.235.1619 A. O. Fratelli Crobu
Iglesias (Cagliari), Italy
205.235.1648 Ospedale "S. Maria di Collemaggio"
L’Aquila, Italy
205.235.1624 Ospedale di Macerata
Macerata, Italy
205.235.1634 P. O. Luigi Sacco
Milan, Italy
205.235.1639 Ospedale Maggiore
Modica (Ragusa), Italy
205.235.1629 A. O. S. Luigi Gonzaga
Orbassano (Torino), Italy
205.235.1604 P. O. R. Silvestrini
Perugia, Italy
205.235.1601 Presidio Ospedaliero di Cisanello
Pisa, Italy
205.235.1643 A. O. Santa Maria degli Angeli
Pordenone, Italy
205.235.1614 Ospedale Misericordia e Dolce
Prato, Italy
205.235.1607 Università degli Studi di Sassari
Sassari, Italy
205.235.1608 ASL 1 di Sassari
Sassari, Italy
205.235.1606 ASL 4 di Terni
Terni, Italy
205.235.1632 ASL 4 - Distretto 2
Torino, Italy
205.235.1633 A. O. Umberto I
Torrette Di Ancona (Ancona), Italy
205.235.1640 P. O. Cà Foncello
Treviso, Italy
205.235.1602 Ospedale di Voghera
Voghera (Pavia), Italy
205.235.1706 Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
205.235.1705 Kameda Medical Center
Kamogawa, Chiba, Japan
205.235.1713 Komaki City Hospital
Komaki, Aichi, Japan
205.235.1712 Kurume University Hospital
Kurume, Fukuoka, Japan
205.235.1708 Shinshu University
Matsumoto, Nagano, Japan
205.235.1702 Iwate Medical University Hospital
Morioka, Iwate, Japan
205.235.1710 Osaka City University Hospital
Osaka, Osaka, Japan
205.235.1711 Kinki University Hospital
Osakasayama, Osaka, Japan
205.235.1701 Hokkaido University
Sapporo, Hokkaido, Japan
205.235.1703 Tohoku University Hospital
Sendai, Miyagi, Japan
205.235.1709 Tosei General Hospital
Seto, Aichi, Japan
205.235.1704 Hiraka General Hospital
Yokote, Akita, Japan
205.235.1801 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.235.1802 Boehringer Ingelheim Investigational Site
Kaunas, Lithuania
205.235.1803 Boehringer Ingelheim Investigational Site
Vilnius, Lithuania
205.235.1901 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
205.235.1902 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
205.235.1903 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.
Col. Mitras Centro, Monterrey, N.L., Mexico
205.235.2002
Guadalajara, Jal., Mexico
205.235.2005
Mexico City, Mexico
205.235.2006 Tlalpan 4000, Pabellón 5, EPOC
Mexico City, Mexico
205.235.2009
Puebla City, Mexico
205.235.2010 Depto. De Ivestigación
Toluca, Mexico
205.235.2003
Zapopan, Jalisco, Mexico
205.235.2110 Poli Longziekten
Almelo, Netherlands
205.235.2105 Lokatie De Lichtenberg
Amersfoort, Netherlands
205.235.2107 Poli Longziekten
Delft, Netherlands
205.235.2106 Lokatie Dordwijk
Dordrecht, Netherlands
205.235.2104 Poli longziekten
Eindhoven, Netherlands
205.235.2102 Martini Ziekenhuis Groningen
Groningen, Netherlands
205.235.2112 Poli Longziekten
Harderwijk, Netherlands
205.235.2115 Poli Longziekten
Heerenveen, Netherlands
205.235.2101 Atrium medisch centrum
Heerlen, Netherlands
205.235.2114 Poli Longziekten
Hengelo, Netherlands
205.235.2108 Poli Longziekten
Leeuwarden, Netherlands
205.235.2109 Poli Longziekten
Rotterdam, Netherlands
205.235.2111 Antonius Ziekenhuis
Sneek, Netherlands
205.235.0211 Boehringer Ingelheim Investigational Site
Auckland, New Zealand
205.235.0212 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand, New Zealand
205.235.2202 Boehringer Ingelheim Investigational Site
Arendal, Norway
205.235.2201 Boehringer Ingelheim Investigational Site
Fredrikstad, Norway
205.235.2205 Boehringer Ingelheim Investigational Site
Sandvika, Norway
205.235.2204 Boehringer Ingelheim Investigational Site
Straume, Norway
205.235.2301 Philippine General Hospital
Manila, Philippines
205.235.2305 University of Santo Tomas Hospital
Manila, Philippines
205.235.2302 Philippine Heart Center
Quezon City, Philippines
205.235.2303 Veterans Memorial Medical Center
Quezon City, Philippines
205.235.2304 Lung Center of the Philippines
Quezon City, Philippines
205.235.2410 Boehringer Ingelheim Investigational Site
Gdansk, Poland
205.235.2407 Boehringer Ingelheim Investigational Site
Katowice, Poland
205.235.2408 Boehringer Ingelheim Investigational Site
Krakow, Poland
205.235.2405 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.235.2409 Boehringer Ingelheim Investigational Site
Lodz, Poland
205.235.2401 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.235.2402 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.235.2403 Boehringer Ingelheim Investigational Site
Warsaw, Poland
205.235.2404 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
205.235.2406 Boehringer Ingelheim Investigational Site
Zabrze, Poland
205.235.2504 Centro Hospitalar de Coimbra
Coimbra, Portugal
205.235.2503 Hospital Pulido Valente
Lisbon, Portugal
205.235.2505 Hospital de Santa Marta
Lisbon, Portugal
205.235.2501 Hospital de São João
Porto, Portugal
205.235.2502 Centro Hospitalar de Vila Nova de Gaia
Vila Nova de Gaia, Portugal
205.235.2601 Boehringer Ingelheim Investigational Site
Moscow, Russia
205.235.2602 Boehringer Ingelheim Investigational Site
Moscow, Russia
205.235.2603 Boehringer Ingelheim Investigational Site
Moscow, Russia
205.235.2605 Boehringer Ingelheim Investigational Site
Moscow, Russia
205.235.2604 Boehringer Ingelheim Investigational Site
Saint Petersburg, Russia
205.235.1904 Boehringer Ingelheim Investigational Site
Singapore, Singapore
205.235.1905 Boehringer Ingelheim Investigational Site
Singapore, Singapore
205.235.1906 Boehringer Ingelheim Investigational Site
Singapore, Singapore
205.235.2701 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
205.235.2702 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
205.235.2703 Boehringer Ingelheim Investigational Site
Martin, Slovakia
205.235.2704 Boehringer Ingelheim Investigational Site
Poprad, Slovakia
205.235.2705 Boehringer Ingelheim Investigational Site
Topoľčany, Slovakia
205.235.2801 Boehringer Ingelheim Investigational Site
Golnik, Slovenia
205.235.2802 Boehringer Ingelheim Investigational Site
Golnik, Slovenia
205.235.2805 Boehringer Ingelheim Investigational Site
Kamnik, Slovenia
205.235.2803 Boehringer Ingelheim Investigational Site
Ljubljana, Slovenia
205.235.2804 Boehringer Ingelheim Investigational Site
Topolšica, Slovenia
205.235.2908
Bloemfontein, South Africa
205.235.2910
Cape Town, South Africa
205.235.2912
Cape Town, South Africa
205.235.2904
Durban, South Africa
205.235.2911
Durban, South Africa
205.235.2902
George, South Africa
205.235.2905
Paarl, South Africa
205.235.2901 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
205.235.2906
Somerset West, South Africa
205.235.2903
Vanderbijlpark, South Africa
205.235.2909
Welkom, South Africa
205.235.3014 Complejo Hospitalario Juan Canalejo
A Coruña, Spain
205.235.3026 Hospital General Universitario de Alicante
Alicante, Spain
205.235.3011 Complejo Hospitalario Infanta Cristina
Badajoz, Spain
205.235.3006 Hospital Germans Trias i Pujol
Badalona (Barcelona), Spain
205.235.3022 Hospital de Cruces
Barakaldo (Bilbao), Spain
205.235.3003 Hospital Clínic i Provincial de Barcelona
Barcelona, Spain
205.235.3008 Hospital Vall d'Hebrón
Barcelona, Spain
205.235.3023 Hospital Dr. Josep Trueta
Girona, Spain
205.235.3004 Hospital General Universitario de Guadalajara
Guadalajara, Spain
205.235.3005 Hospital General San Jorge de Huesca
Huesca, Spain
205.235.3021 Hospital de Jerez de la Frontera
Jerez de la Frontera, Spain
205.235.3010 Hospital Severo Ochoa
Leganés, Madrid, Spain
205.235.3009 Hospital Clínico San Carlos
Madrid, Spain
205.235.3013 Clínica Puerta de Hierro
Madrid, Spain
205.235.3017 Hospital Ramón y Cajal
Madrid, Spain
205.235.3020 Hospital Universitario La Paz
Madrid, Spain
205.235.3028 Hospital Universitario de la Princesa
Madrid, Spain
205.235.3031 Hospital Gregorio Marañón
Madrid, Spain
205.235.3036 Hospital 12 de Octubre
Madrid, Spain
205.235.3033 Hospital General Carlos Haya
Málaga, Spain
205.235.3027 Complejo Asistencial Son Dureta
Palma de Mallorca, Spain
205.235.3024 Hospital de Montecelo
Pontevedra, Spain
205.235.3016 Hospital Universitari de Sant Joan
Reus (Tarragona), Spain
205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell
Sabadell (Barcelona), Spain
205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria
Santa Cruz de Tenerife, Spain
205.235.3039 Hospital Universitario Marqués de Valdecilla
Santander, Spain
205.235.3019 Hospital Vírgen de la Macarena
Seville, Spain
205.235.3035 Hospital Universitario Vírgen del Rocío
Seville, Spain
205.235.3001 Hospital Mutua Terrassa
Terrassa (Barcelona), Spain
205.235.3002 Hospital Clínico Universitario de Valencia
Valencia, Spain
205.235.3025 Hospital Universitario Dr. Peset
Valencia, Spain
205.235.3032 Hospital Arnau de Vilanova
Valencia, Spain
205.235.3034 Hospital La Fe
Valencia, Spain
205.235.3018 Complejo Hospitalario Xeral - Cíes
Vigo, Spain
205.235.3030 Hospital Miguel Servet
Zaragoza, Spain
205.235.3038 Hospital Clínico Lozano Blesa
Zaragoza, Spain
205.235.3202 Boehringer Ingelheim Investigational Site
Basel, Switzerland
205.235.3203 Universitätsspital Basel
Basel, Switzerland
205.235.3204 Boehringer Ingelheim Investigational Site
Faltigberg, Switzerland
205.235.3205 Boehringer Ingelheim Investigational Site
Lugano, Switzerland
205.235.3206 Boehringer Ingelheim Investigational Site
Montana, Switzerland
205.235.3208 Boehringer Ingelheim Investigational Site
Winterthur, Switzerland
205.235.3201 Boehringer Ingelheim Investigational Site
Zurich, Switzerland
205.235.3301 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
205.235.3302 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
205.235.3303 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
205.235.3402 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
205.235.3403 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
205.235.3404 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
205.235.3401 Boehringer Ingelheim Investigational Site
Chiang Mai, Thailand
205.235.3405 Boehringer Ingelheim Investigational Site
Khon Kaen, Thailand
205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi
Adana, Turkey (Türkiye)
205.235.3506 Hacettepe Tip Fakultesi
Ankara, Turkey (Türkiye)
205.235.3507 Ankara SSK Diskapi Egitim Hastanesi
Ankara, Turkey (Türkiye)
205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi
Ankara, Turkey (Türkiye)
205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye
Erzurum, Turkey (Türkiye)
205.235.3511 Osmangazi Universitesi Tip Fakültesi
Eskişehir, Turkey (Türkiye)
205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi
Istanbul, Turkey (Türkiye)
205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi
Istanbul, Turkey (Türkiye)
205.235.3503 Tophanelioglu Cad. No: 13/15
Istanbul, Turkey (Türkiye)
205.235.3504 Cevizli E5 Karayolu
Istanbul, Turkey (Türkiye)
205.235.3505 Istanbul Universitesi Tip Fakültesi
Istanbul, Turkey (Türkiye)
205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD
Izmir, Turkey (Türkiye)
205.235.3615 Boehringer Ingelheim Investigational Site
Aberdeen, United Kingdom
205.235.3611 Boehringer Ingelheim Investigational Site
Chertsey, United Kingdom
205.235.3613 Boehringer Ingelheim Investigational Site
Chesterfield, United Kingdom
205.235.3608 Boehringer Ingelheim Investigational Site
Cottingham, Hull, United Kingdom
205.235.3605 Boehringer Ingelheim Investigational Site
Exeter, United Kingdom
205.235.3602 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
205.235.3610 Boehringer Ingelheim Investigational Site
Leeds, United Kingdom
205.235.3607 Boehringer Ingelheim Investigational Site
Leicester, United Kingdom
205.235.3604 Boehringer Ingelheim Investigational Site
Middleton, United Kingdom
205.235.3612 Boehringer Ingelheim Investigational Site
Nottingham, United Kingdom
205.235.3616 Boehringer Ingelheim Investigational Site
Paisley, United Kingdom
205.235.3614 Boehringer Ingelheim Investigational Site
Penarth, United Kingdom
205.235.3603 Boehringer Ingelheim Investigational Site
Plymouth, United Kingdom
205.235.3609 Boehringer Ingelheim Investigational Site
Sheffield, United Kingdom
205.235.3601 Boehringer Ingelheim Investigational Site
Solihull, Birmingham, United Kingdom
Related Publications (12)
Rabe KF, Halpin DMG, Han MK, Miravitlles M, Singh D, Gronke L, Voss F, Martinez FJ. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020 Jul 9;21(1):177. doi: 10.1186/s12931-020-01431-y.
PMID: 32646424DERIVEDTashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT(R) trial. Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.
PMID: 30290801DERIVEDCelli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT(R) trial. Respir Res. 2016 May 4;17(1):48. doi: 10.1186/s12931-016-0361-4.
PMID: 27141828DERIVEDGoossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med. 2014 Oct 18;14:163. doi: 10.1186/1471-2466-14-163.
PMID: 25326750DERIVEDTashkin DP, Li N, Kleerup EC, Halpin D, Celli B, Decramer M, Elashoff R. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respir Res. 2014 Aug 31;15(1):102. doi: 10.1186/s12931-014-0102-5.
PMID: 25175805DERIVEDJanssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, Decramer M. Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT(R)). Respir Med. 2013 Sep;107(9):1409-16. doi: 10.1016/j.rmed.2013.04.015. Epub 2013 May 25.
PMID: 23714653DERIVEDTashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 >/= 60% participating in the UPLIFT(R) trial. COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.
PMID: 22432932DERIVEDKesten S, Celli B, Decramer M, Liu D, Tashkin D. Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial. Respir Res. 2011 Sep 28;12(1):129. doi: 10.1186/1465-9921-12-129.
PMID: 21955733DERIVEDTashkin D, Celli B, Kesten S, Lystig T, Decramer M. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.
PMID: 20418083DERIVEDTroosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.
PMID: 20185426DERIVEDDecramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.
PMID: 19716598DERIVEDTashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.
PMID: 18836213DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Limitations and Caveats
Tio patients had significantly longer drug exposure,thus had increased chance of AE.Simple frequencies are biased for AE comparisons;exposure-adjusted incidence rates (IR) should be used. IR for serious AE(\>1% patients) are in Outcome Measures.
Results Point of Contact
- Title
- Boehringer Ingelheim Pharmaceuticals
- Organization
- Boehringer Ingelheim Pharmaceuticals
Study Officials
- STUDY CHAIR
Boehringer Ingelheim
Boehringer Ingelheim
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 2, 2005
First Posted
September 5, 2005
Study Start
December 1, 2002
Primary Completion
February 1, 2008
Last Updated
May 20, 2014
Results First Posted
August 17, 2009
Record last verified: 2014-04